4-(10,11-dihydrodibenzo[a,d]cyclohepten-5-ylidenemethyl)benzonitrile | 27980-51-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 二苯并环庚烯
• 英文名称: 4-(10,11-dihydrodibenzo[a,d]cyclohepten-5-ylidenemethyl)benzonitrile
• 英文别名: 4-(2-Tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,11,13-hexaenylidenemethyl)benzonitrile
• CAS: 27980-51-4
• 化学式: C₂₃H₁₇N
• 分子量: 307.395
• InChiKey: RGASNHMMGCRCSA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.1
• 重原子数：
  24
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  23.8
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  10,11-二氢二苯并[a,b]环庚烯-5-酮 、 (4-氰基苄基)亚磷酸二乙酯 在 sodium hydride 作用下， 以 二乙二醇二甲醚 为溶剂， 生成 4-(10,11-dihydrodibenzo[a,d]cyclohepten-5-ylidenemethyl)benzonitrile
  参考文献：
  名称：

  Fulvenes and Thermochromic Ethylenes. Part 57. The Wittig-Horner Reaction with Fulvene Ketones and Related Ketones¹

  摘要：

  DOI：

  10.1055/s-1970-21594

文献信息

• Tricyclic steroid hormone nuclear receptor modulators
  申请人：Coghlan Joseph Michael

  公开号：US20060063759A1

  公开（公告）日：2006-03-23

  The present invention relates to methods of treating pathological disorders susceptible to steroid hormone nuclear receptor modulation comprising administering to a patient in need thereof an effective amount of a compound of the formula (I): or a pharmaceutically acceptable salt thereof. In addition, the present invention provides novel pharmaceutical compounds of Formula (I), including the pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions which comprise as an active ingredient a compound of Formula (I).

  本发明涉及治疗对类固醇激素核受体调节敏感的病理性疾病的方法，包括向需要治疗的患者施用化合物（I）的有效量或其药学上可接受的盐。此外，本发明提供了公式（I）的新型药物化合物，包括其药学上可接受的盐，以及含有公式（I）化合物作为活性成分的药物组合物。
• TRICYCLIC STEROID HORMONE NUCLEAR RECEPTOR MODULATORS
  申请人：Coghlan Michael Joseph

  公开号：US20090149445A1

  公开（公告）日：2009-06-11

  The present invention relates to methods of treating pathological disorders susceptible to steroid hormone nuclear receptor modulation comprising administering to a patient in need thereof an effective amount of a compound of the formula: or a pharmaceutically acceptable salt thereof. In addition, the present invention provides novel pharmaceutical compounds of Formula I, including the pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions which comprise as an active ingredient a compound of Formula I.

  本发明涉及治疗容易受到类固醇激素核受体调节的病理性疾病的方法，包括向需要治疗的患者施用化合物的有效量，该化合物的公式为：或其药学上可接受的盐。此外，本发明提供了公式I的新型药物化合物，包括其药学上可接受的盐，以及含有公式I化合物作为活性成分的药物组合物。
• US7411072B2
  申请人：——

  公开号：US7411072B2

  公开（公告）日：2008-08-12
• [EN] TRICYCLIC STEROID HORMONE NUCLEAR RECEPTOR MODULATORS<br/>[FR] MODULATEURS TRICYCLIQUES DU RECEPTEUR NUCLEAIRE DES HORMONES STEROIDIENNES
  申请人：LILLY CO ELI

  公开号：WO2004052847A2

  公开（公告）日：2004-06-24

  The present invention relates to methods of treating pathological disorders susceptible to steroid hormone nuclear receptor modulation comprising administering to a patient in need thereof an effective amount of a compound of the formula (I): or a pharmaceutically acceptable salt thereof. In addition, the present invention provides novel pharmaceutical compounds of Formula (I), including the pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions which comprise as an active ingredient a compound of Formula (I).
• Fulvenes and Thermochromic Ethylenes. Part 57. The Wittig-Horner Reaction with Fulvene Ketones and Related Ketones¹
  作者：Ernst D. BERGMANN、Abraham SOLOMONOVICI

  DOI：10.1055/s-1970-21594

  日期：——